• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Biotricity Inc.

    6/30/25 9:20:12 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email
    NT 10-K 1 formnt10-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q

    ☐ Form N-SAR ☐ Form N-CSR

     

    For Period Ended: March 31, 2025

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

    ☐ Transition Report on Form N-SAR

     

    For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission

    has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

     

    PART I - REGISTRANT INFORMATION

     

    BIOTRICITY INC.

    Full name of Registrant

     

    N/A

    Former Name if Applicable

     

    203 Redwood Shores Parkway, Suite 600

    Address of Principal Executive Office (Street and Number)

     

    Redwood City, CA 94065

    City, State and Zip Code

     

     

     

     

     

     

    PART II - RULE 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report portion thereof could not be filed within the prescribed time period.

     

    The compilation, dissemination and review of the information required to be presented in the Form 10-K for the relevant period has imposed time constraints that have rendered timely filing of the Form 10-K impracticable without undue hardship and expense to the registrant. The registrant undertakes the responsibility to file such report no later than fifteen days after its original prescribed due date.

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

      John Ayanoglou (800)

    590-4155

      (Name) (Area Code) (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). Yes ☒ No ☐

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    BIOTRICITY INC.

    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: June 30, 2025 By: /s/ John Ayanoglou
        John Ayanoglou
        Chief Financial Officer

     

     

     

    Get the next $BTCY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BTCY
    SEC Filings

    View All

    SEC Form 10-Q filed by Biotricity Inc.

    10-Q - BIOTRICITY INC. (0001630113) (Filer)

    8/14/25 7:01:14 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Biotricity Inc.

    10-K - BIOTRICITY INC. (0001630113) (Filer)

    7/15/25 5:27:01 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form NT 10-K filed by Biotricity Inc.

    NT 10-K - BIOTRICITY INC. (0001630113) (Filer)

    6/30/25 9:20:12 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

    REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e

    8/14/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

    Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid

    8/12/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

    FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

    7/17/25 9:33:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biotricity downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Biotricity from Buy to Neutral

    11/20/23 7:21:43 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Biotricity with a new price target

    Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

    3/7/22 9:01:18 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Biotricity with a new price target

    HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00

    11/23/21 6:29:32 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rosa David A

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/15/23 4:22:52 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Al-Siddiq Waqaas

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/14/23 4:26:54 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ayanoglou John

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/13/23 4:10:59 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Financials

    Live finance-specific insights

    View All

    Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

    REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e

    8/14/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

    Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid

    8/12/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

    FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

    7/17/25 9:33:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Biotricity Inc.

    SC 13G - BIOTRICITY INC. (0001630113) (Subject)

    8/8/24 6:09:48 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care